Respiratory syncytial virus and parainfluenza virus vaccines

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 1146-1153

  Karron, Ruth A ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902057991     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00058-6     Document Type: Chapter

References (201)

1. Hall C.B., Weinberg G.A., Iwane M.K., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
2. Nair H., Nokes D.J., Gessner B.D., et al. Global Burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
3. Weinberg G.A., et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009, 154:694-699.
4. Kapikian A.Z., Mitchell R.H., Chanock R.M., et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
5. Groothuis J.R., Simões E.A.F., Levin M.J., et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993, 329:1524-1530.
6. Committee on Infectious Diseases From the American Academy of Pediatrics: Policy statements: modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009, 124:1694-1701.
7. Paradiso P.R., Hildreth S.W., Hogerman D.A., et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 1994, 13:792-798.
8. Swanson K.A., Settembre E.C., Shaw C.A., et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 2011, 108:9619-9624.
9. Karron R.A., Wright P.F., Belshe R.B., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005, 191:1093-1104.
10. Collins P.L., Murphy B.R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2005, 2:166-173.
11. Crowe J.E., Collins P.L. Respiratory syncytial virus. Fields Virology 2007, 1313-1351. Wolters Kluwer/Lippincott Williams & Wilkins, New York. D.M. Knipe, P.M. Howley (Eds.).
12. Hall C.B. Prospects for a respiratory syncytial virus vaccine. Science 1994, 265:1393-1394.
13. Hall C.B., Weinberg G.A., Iwane M.K., et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009, 360:588-598.
14. Shay D.K., Holman R.C., Newman R.D., et al. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999, 282:1440-1446.
15. Nair H., Nokes D.J., Gessner B.D., et al. Global Burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010, 375:1545-1555.
16. Fouillard L., Mouthon L., Laporte J.P., et al. Severe respiratory syncytial virus pneumonia after autologous bone marrow transplantation: a report of three cases and review. Bone Marrow Transplant 1992, 9:97-100.
17. Falsey A.R., Treanor J.J., Betts R.F. Viral respiratory infections in the institutionalized elderly: clinical and epidemiologic findings. JAGS 1992, 40:115-119.
18. Han L.L., Alexander J.P., Anderson L.J. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 1999, 179:25-30.
19. Falsey A.R. Respiratory syncytial virus infection in older persons. Vaccine 1998, 16:1775-1778.
20. Falsey A.R., Walsh E.E. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000, 13:371-384.
21. Falsey A.R., Formica M.A., Hennessey P.A. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006, 173:639-643.
22. Mullooly J.P., Bridges C.B., Thompson W.W., et al. Influenza- and RSV-associated hospitalizations among adults. Vaccine 2007, 25:846-855.
23. Institute of Medicine Diseases of importance in the United States. New Vaccine Development: Establishing Priorities 1985, 397-409. National Academy Press, Washington, DC. Committee on Issues Priorities for New Vaccine Development (Ed.).
24. Weinberg G.A., et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 2009, 154:694-699.
25. Reed G., Jewett P.H., Thompson J., et al. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children < 5 years old. J Infect Dis 1997, 175:807-813.
26. Glezen W.P., Denny F.W. Epidemiology of acute lower respiratory disease in children. N Engl J Med 1973, 288:498-505.
27. Glezen W.P., Frank A.L., Taber L.H., et al. Parainfluenza virus type 3: seasonality and risk of infection and reinfection in young children. J Infect Dis 1984, 150:851-857.
28. Wright P.F. Parainfluenza viruses. Textbook of Human Virology 1984, 299-307. PSG Publishing, Littleton, MA. 2nd ed. R.B. Belshe (Ed.).
29. Karron R.A., O'Brien K.L., Froehlich J.L., et al. Molecular epidemiology of a parainfluenza type 3 virus outbreak on a pediatric ward. J Infect Dis 1993, 167:1441-1445.
30. Heilman C.A. Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990, 161:402-406.
31. Nichols W.G., Corey L., Gooley T., et al. Parainfluenza virus infections after hematopoietic stem cell transplantation: risk factors, response to antiviral therapy, and effect on transplant outcome. Blood 2001, 98:573-578.
32. Cortez K.J., Erdman D.D., Peret T.C., et al. Outbreak of human parainfluenza virus 3 infections in a hematopoietic stem cell transplant population. J Infect Dis 2001, 184:1093-1097.
33. Murphy B.R., Hall S.L., Kulkarni A.B., et al. An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines. Virus Res 1994, 32:13-36.
34. Clements M.L., Makhene M.K., Karron R.A., et al. Effective immunization with live attenuated influenza A virus can be achieved in early infancy. J Infect Dis 1996, 173:44-51.
35. Karron R.A., Steinhoff M.C., Subbarao E.K., et al. Safety and immunogenicity of a cold-adapted influenza A (H1N1) reassortant virus vaccine administered to infants less than six months of age. Pediatr Infect Dis J 1995, 14:10-16.
36. Kim H.W., Canchola J.G., Brandt C.D., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 1969, 89:422-434.
37. Kapikian A.Z., Mitchell R.H., Chanock R.M., et al. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 1969, 89:405-421.
38. Fulginiti V.A., Eller J.J., Sieber O.F., et al. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines: an aqueous trivalent parainfluenza virus vaccine and an alum-precipated respiratory syncytial virus vaccine. Am J Epidemiol 1969, 89:435-448.
39. Hall C.B., Kopelman A.E., Douglas R.G., et al. Neonatal respiratory syncytial virus infection. N Engl J Med 1979, 300:393-396.
40. Heikkinen T., Thint M., Chonmaitree T. Prevalence of various respiratory viruses in the middle ear during acute otitis media. N Engl J Med 1999, 340:260-264.
41. Cunningham C.K., McMillan J.A., Gross S.J. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991, 88:527-532.
42. Berkovich S. Acute respiratory illness in the premature nursery associated with respiratory syncytial virus infections. Pediatrics 1964, 34:753-760.
43. Groothuis J.R., Gutierrez K.M., Lauer B.A. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988, 82:199-203.
44. MacDonald N.E., Hall C.B., Suffin S.C., et al. Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med 1982, 307:397-400.
45. Fishaut M., Tubergen D., McIntosh K. Cellular response to respiratory viruses with particular reference to children with disorders of cell-mediated immunity. J Pediatr 1980, 96:179-186.
46. McIntosh K., Kurachek S.C., Cairns L.M., et al. Treatment of respiratory viral infection in an immunodeficient infant with ribavirin aerosol. AJDC 1984, 138:305-308.
47. Hall C.B. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 2001, 344:1917-1928.
48. Hiatt P.W., Grace S.C., Kozinetz C.A., et al. Effects of viral lower respiratory tract infection on lung function in infants with cystic fibrosis. Pediatrics 1999, 103:619-626.
49. Armstrong D., Grimwood K., Carlin J.B., et al. Severe viral respiratory infections in infants with cystic fibrosis. Pediatr Pulmonol 1998, 26:371-379.
50. Karron R.A., Singleton R.J., Bulkow L., et al. Severe respiratory syncytial virus disease in Alaska native children. RSV Alaska Study Group. J Infect Dis 1999, 180:41-49.
51. Bockova J., O'Brien K.L., Oski J., et al. Respiratory syncytial virus infection in Navajo and White Mountain Apache children. Pediatrics 2002, 110(2 pt 1):e20. 10.1542/peds.110.2.e20.
52. Martinez F.D., Wright A.L., Taussig L.M., et al. Asthma and wheezing in the first six years of life. N Engl J Med 1995, 332:133-136.
53. Kattan M. Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. J Pediatr 1999, 135:S8-13.
54. Hall C.B., Geiman J.M., Biggar R., et al. Respiratory syncytial virus infections within families. N Engl J Med 1976, 294:414-419.
55. Falsey A.R., Cunningham C.K., Barker W.H., et al. Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J Infect Dis 1995, 172:389-394.
56. Falsey A.R., Walsh E.E. Viral pneumonia in older adults. Clin Infect Dis 2006, 42:518-524.
57. Whimbey E., Ghosh S. Respiratory syncytial virus infections in immunocompromised adults. Curr Clin Top Infect Dis 2000, 20:232-255.
58. Englund J.A., Sullivan C.J., Jordan M.C., et al. Respiratory syncytial virus infection in immunocompromised adults. Ann Intern Med 1988, 109:203-208.
59. Whimbey E., Champlin R.E., Couch R.B., et al. Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. Clin Infect Dis 1996, 22:778-782.
60. Hertz M.I., Englund J.A., Snover D., et al. Respiratory syncytial virus induced acute lung injury in adult patients with bone marrow transplants: a clinical approach and review of the literature. Medicine 1989, 68:269-281.
61. Whimbey E., Couch R.B., Englund J.A., et al. Respiratory syncytial virus pneumonia in hospitalized adult patients with leukemia. Clin Infect Dis 1995, 21:376-379.
62. Harrington R.D., Hooton T.M., Hackman R.C., et al. An outbreak of respiratory syncytial virus in a bone marrow transplant center. J Infect Dis 1992, 165:987-993.
63. Vilchez R.A., Dauber J., Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection-myth or reality?. Am J Transplant 2003, 3:245-249.
64. King J.C., Burke A.R., Clemens J.D., et al. Respiratory syncytial virus illnesses in human immunodeficiency virus- and noninfected children. Pediatr Infect Dis J 1993, 12:733-739.
65. Madhi S.A., Venter M., Madhi A., et al. Differing manifestations of respiratory syncytial virus-associated severe lower respiratory tract infections in human immunodeficiency virus type 1-infected and uninfected children. Pediatr Infect Dis J 2001, 20:164-170.
66. Madhi S.A., Ramasamy N., Petersen K., et al. Severe lower respiratory tract infections associated with human parainfluenza viruses 1-3 in children infected and noninfected with HIV type 1. Eur J Clin Microbiol Infect Dis 2002, 21:499-505.
67. Hendricks D.A., McIntosh K., Patterson J.L. Further characterization of the soluble form of the G glycoprotein of respiratory syncytial virus. J Virol 1988, 62:2228-2233.
68. Collins P.L., Chanock R.M., Murphy B. Respiratory syncytial virus. Fields Virology, vol 1 2001, 1443-1475. Lippincott Williams & Wilkins, Philadelphia. 4th ed. D.M. Knipe, P.M. Howley (Eds.).
69. Polack F.P., Irusta P.M., Hoffman S.J., et al. The cysteine-rich region of respiratory syncytial virus attachment protein inhibits innate immunity elicited by the virus and endotoxin. Proc Natl Acad Sci U S A 2005, 102:8996-9001.
70. Spann K.M., Tran K.C., Collins P.L. Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol 2005, 79:5353-5362.
71. Bitko V., Shulyayeva O., Mazumder B., et al. Nonstructural proteins of respiratory syncytial virus suppress premature apoptosis by an NF-kappaB-dependent, interferon-independent mechanism and facilitate virus growth. J Virol 2005, 81:1786-1795. (2007).
72. Coates H.V., Alling D.W., Chanock R.M. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 1966, 83:299-313.
73. Johnson P.R., Olmsted R.A., Prince G.A., et al. Antigenic relatedness between glycoproteins of human respiratory syncytial virus subgroups A and B: evaluation of the contributions of F and G glycoproteins to immunity. J Virol 1987, 61:3163-3166.
74. Taylor C.E., Morrow S., Scott M., et al. Comparative virulence of respiratory syncytial virus subgroups A and B. Lancet 1989, 1:777-778.
75. McConnochie K.M., Hall C.B., Walsh E.E., et al. Variation in severity of respiratory syncytial virus infections with subtype. J Pediatr 1990, 117:52-62.
76. Mufson M.A., Belshe R.B., Orvell C., et al. Subgroup characteristics of respiratory syncytial virus strains recovered from children with two consecutive infections. J Clin Microbiol 1987, 25:1535-1539.
77. Chanock R.M., McIntosh K. Parainfluenza viruses. Virology 1990, 963-988. Raven Press, New York. 2nd ed. B.N. Fields, D.M. Knipe (Eds.).
78. Moscona A. Entry of parainfluenza virus into cells as a target for interrupting childhood respiratory disease. J Clin Invest 2005, 115:1688-1698.
79. Henderson F.W., Collier A.M., Clyde W.A., et al. Respiratory-syncytial-virus infections, reinfections and immunity: a prospective, longitudinal study in young children. N Engl J Med 1979, 300:530-534.
80. Parrott R.H., Vargosko A., Luckey A., et al. Clinical features of infection with hemadsorption viruses. N Engl J Med 1959, 260:731-738.
81. Parrott R.H., Vargosko A.J., Kim H.W., et al. Myxoviruses: parainfluenza. Am J Pub Health 1962, 52:907-917.
82. Mufson M.A., Levin M.J., Wash R.E., et al. Epidemiology of respiratory syncytial virus infection among infants and children in Chicago. Am J Epidemiol 1973, 98:88-95.
83. Spence L., Barratt N. Respiratory syncytial virus associated with acute respiratory infections in Trinidadian patients. Am J Epidemiol 1968, 88:257-266.
84. Hendry R.M., Burns J.C., Walsh E.E., et al. Strain-specific serum antibody responses in infants undergoing primary infection with respiratory syncytial virus. J Infect Dis 1988, 157:640-647.
85. Hendry R.M., Pierik L.T., McIntosh K. Prevalence of respiratory syncytial virus subgroups over six consecutive outbreaks: 1981-1987. J Infect Dis 1989, 160:185-190.
86. Mufson M.A., Belshe R.B., Orvell C., et al. Respiratory syncytial virus epidemics: variable dominance of subgroups A and B strains among children, 1981-1986. J Infect Dis 1988, 157:143-148.
87. Akerlind-Stopner B., Norrby E. Occurrence of respiratory syncytial virus subtypes A and B strains in Sweden. J Med Virol 1986, 19:241-247.
88. Iwane M.K., Edwards K.M., Szilagyi P.G., et al. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004, 113:1758-1764.
89. Weinberg G.A., Hall C.B., Walker F.J., et al. Parainfluenza Virus Infection of Young Children: Burden of Hospitalization and Seasonal Patterns of Infection 2004, Society for Pediatric Research, San Francisco, CA.
90. Billaud G., Morfin F., Vabret A., et al. Human parainfluenza virus type 4 infections: a report of 20 cases from 1998 to 2002. J Clin Virol 2005, 34:48-51.
91. Lindquist S.W., Darnule A., Istas A., et al. Parainfluenza virus type 4 infections in pediatric patients. Pediatr Infect Dis J 1997, 16:34-38.
92. Fairchok M.P., Martin E.T., Kuypers J., et al. A prospective study of parainfluenza virus type 4 infections in children attending daycare. Pediatr Infect Dis J 2011, 30:714-716.
93. Hall C.B., Douglas R.G. Modes of transmission of respiratory syncytial virus. J Pediatr 1981, 99:100-103.
94. Hall C.B., Douglas R.G., Schnabel K.C., et al. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 1981, 33:779-783.
95. Hall C.B. Nosocomial respiratory syncytial virus infections: the 'Cold War' has not ended. Clin Infect Dis 2000, 31:590-596.
96. Nichols W.G., Erdman D.D., Han A., et al. Prolonged outbreak of human parainfluenza virus 3 infection in a stem cell transplant outpatient department: insights from molecular epidemiologic analysis. Biol Blood Marrow Transplant 2004, 10:58-64.
97. Haynes L.M., Moore D.D., Kurt-Jones E.A., et al. Involvement of Toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 2001, 75:10730-10737.
98. Kurt-Jones E.A., Popova L., Kwinn L., et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 2000, 1:398-401.
99. Beem M. Repeated infections with respiratory syncytial virus. J Immunol 1987, 98:1115-1122.
100. Hall C.B., Walsh E.E., Long C.E. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991, 163:693-698.
101. Brandenburg A.H., Kleinjan A., van Het L.B., et al. Type 1-like immune response is found in children with respiratory syncytial virus infection regardless of clinical severity. J Med Virol 2000, 62:267-277.
102. Cannon M.J., Openshaw P.J.M., Askonas B.A. Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus. J Exp Med 1988, 168:1163-1168.
103. Aung S., Graham B.S. IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity in. J Immunol 2000, 164:3487-3493.
104. Hassantoufighi A., et al. Respiratory syncytial virus replication is prolonged by a concomitant allergic response. Clin Exp Immunol 2007, 148:218-229.
105. Graham B.S., Bunton L.A., Wright P.F., et al. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J Clin Invest 1991, 88:1026-1033.
106. Graham B.S. Biological challenges and technological opportunities for respiratory syncytial virus vaccine development. Immunol Rev 2011, 239:149-166.
107. Prince G.A., Horswood R.L., Camargo E., et al. Mechanisms of immunity to respiratory syncytial virus in cotton rats. Infect Immun 1983, 42:81-87.
108. Walsh E.E., Schlesinger J.J., Brandriss M.W. Protection from respiratory syncytial virus infection in cotton rats by passive transfer of monoclonal antibodies. Infect Immun 1984, 43:756-758.
109. Prince G.A., Horswood R.L., Chanock R.M. Quantitative aspects of passive immunity to respiratory syncytial virus infection in infant cotton rats. J Virol 1985, 55:517-520.
110. Mills V.J., Van Kirk J.E., Wright P.F., et al. Experimental respiratory syncytial virus infection of adults. J Immunol 1971, 107:123-130.
111. McIntosh K., Masters H.B., Orr I., et al. The immunologic response to infection with respiratory syncytial virus in infants. J Infect Dis 1978, 138:24-32.
112. Glezen W.P., Paredes A., Allison J.E., et al. Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody level. J Pediatr 1981, 98:708-715.
113. Holberg C.J., Wright A.L., Martinez F.D., et al. Risk factors for respiratory syncytial virus-associated lower respiratory illnesses in the first year of life. Am J Epidemiol 1991, 133:1135-1151.
114. Glezen W.P., Taber L.H., Frank A.L., et al. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543-546.
115. Murphy B.R., Alling D.W., Snyder M.H., et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 1986, 24:894-898.
116. Groothuis J.R., Simões E.A.F., Levin M.J., et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993, 329:1524-1530.
117. Hemming V.G., Prince G.A., Groothuis J.R., et al. Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections. Clin Microbiol Rev 1995, 8:22-33.
118. Wright P.F., Karron R.A., Belshe R.B., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 2000, 182:1331-1342.
119. Chanock R.M., Parrott R.H., Johnson K.M., et al. Myxoviruses: parainfluenza. Am Rev Respir Dis 1963, 88:152-166.
120. Smith C.B., Purcell R.H., Bellanti J.A., et al. Protective effect of antibody to parainfluenza type 1 virus. N Engl J Med 1966, 275:1145-1152.
121. Tremonti L.P., Lin J.L., Jackson G.G. Neutralizing activity in nasal secretions and serum in resistance of volunteers to parainfluenza virus type 2. J Immunol 1968, 101:572-577.
122. Tao T., Davoodi F., Cho C.J., et al. A live attenuated recombinant chimeric parainfluenza virus (PIV) candidate vaccine containing the hemagglutinin-neuraminidase and fusion glycoproteins of PIV1 and the remaining proteins from PIV3 induces resistance to PIV1 even in animals immune to PIV3. Vaccine 2000, 18:1359-1366.
123. PREVENT Study Group Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 99:93-99.
124. IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537.
125. American Academy of Pediatrics: Committee on Infectious Diseases Respiratory syncytial virus immune globulin intravenous: indications for use. Pediatrics 1997, 99:645-650.
126. American Academy of Pediatrics Policy statements: modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009, 124:1694-1701.
127. Feltes T.F., Cabalka A.K., Meissner H.C., et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003, 143:532-540.
128. Boeckh M., Berrey M.M., Bowden R.A., et al. Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. J Infect Dis 2001, 184:350-354.
129. Rodriguez W.J., Gruber W.C., Welliver R.C., et al. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group. Pediatrics 1997, 99:454-461.
130. Malley R., Devincenzo J., Ramilo O., et al. Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. J Infect Dis 1998, 178:1555-1561.
131. Venkatesh M.P., Weisman L.E. Prevention and treatment of respiratory syncytial virus infection in infants: an update. Expert Rev Vaccines 2006, 5:261-268.
132. Mejias A., Chavez-Bueno S., Rios A.M., et al. Comparative effects of two neutralizing anti-respiratory syncytial virus (RSV) monoclonal antibodies in the RSV murine model: time versus potency. Antimicrob Agents Chemother 2005, 49:4700-4707.
133. Wu H., Pfarr D.S., Tang Y., et al. Ultra-potent antibodies against respiratory syncytial virus: effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 2005, 350:126-144.
134. Carbonell-Estrany X., Simões E.A., Dagan R., et al. Motavizumab Study Group. Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial. Pediatrics 2010, 125:e35-e51. doi:10.1371/journal.ppat.0030009.
135. Chandran A., Millar E., Weatherholtz R. RSV Prevention Study Team. Safety and efficacy of motavizumab in the prevention of RSV disease in healthy Native American infants. Poster Presentation, #4460.5 May 2-6, 2008, Honolulu, HI, Honolulu, HI.
136. Hurwitz J.L. Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections. Pediatr Infect Dis J 2008, 27(Suppl. 10):S126-S128.
137. Mok H., Lee S., Utley T.J., et al. Venezuelan equine encephalitis virus replicon particles encoding respiratory syncytial virus surface glycoproteins induce protective mucosal responses in mice and cotton rats. J Virol 2007, 81:13710-13722.
138. Elliott M.B., Chen T., Terio N.B., et al. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques. Vaccine 2007, 25:7132-7144.
139. Chin J., Magoffin R.L., Shearer L.A., et al. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 1969, 89:449-463.
140. Murphy B.R., Prince G.A., Walsh E.E., et al. Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986, 24:197-202.
141. Kim H.W., Leikin S.L., Arrobio J., et al. Cell-mediated immunity to respiratory syncytial virus induced by inactivated vaccine or by infection. Pediatr Res 1976, 10:75-78.
142. Graham B.S., Henderson G.S., Tang Y-W, et al. Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus. J Immunol 1993, 151:2032-2040.
143. Waris M.E., Tsou C., Erdman D.D., et al. Respiratory syncytial virus infection in BALB/c mice previously immunized with formalin-inactivated virus induces enhanced pulmonary inflammatory response with a predominant Th2-like cytokine pattern. J Virol 1996, 70:2852-2860.
144. + T cells. J Virol 1992, 66:7444-7451.
145. + T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection. Eur J Immunol 1997, 27:3341-3349.
146. Tang Y-W, Neuzil K.M., Fischer J.E., et al. Determinants and kinetics of cytokine expression patterns in lungs of vaccinated mice challenged with respiratory syncytial virus. Vaccine 1997, 15:597-602.
147. Neuzil K.M., Johnson J.E., Tang Y-W, et al. Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine. Vaccine 1997, 15:525-532.
148. Crowe J.E.J., Collins P.L., Chanock R.M., et al. Vaccines against respiratory syncytial virus and parainfluenza virus type 3. New Generation Vaccines 1997, 711-725. Marcel Dekker, New York. M.M. Levine, G.C. Woodrow, J.B. Kaper (Eds.).
149. Tang Y.W., Graham G.S. Interleukin-12 treatment during immunization elicits a T helper cell type 1-like immune response in mice challenged with respiratory syncytial virus and improves vaccine immunogenicity. J Infect Dis 1995, 172:734-738.
150. Polack F.P., Teng M.N., Collins P.L., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 2002, 196:859-865.
151. Delgado M.F., Coviello S., Monsalvo A.C., et al. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 2009, 15:34-41.
152. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21:3465-3467.
153. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 1996, 14:1214-1218.
154. Falsey A.R., Walsh E.E. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 1997, 15:1130-1132.
155. Belshe R.B. Immunogenicity of purified F glycoprotein of respiratory syncytial virus: clinical and immune responses to subsequent natural infection in children. J Infect Dis 1993, 168:1024-1029.
156. Tristram D.A., Welliver R.C., Mohar C.K., et al. Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old. J Infect Dis 1993, 167:191-195.
157. Piedra P.A., Grace S., Jewell A., et al. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 1996, 15:23-31.
158. Groothuis J.R., King S.J., Hogerman D.A., et al. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 1998, 177:467-469.
159. Falsey A.R., Walsh E.E., Capellan J., et al. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines-nonadjuvanted vaccine or vaccine adjuvanted with alum-given concomitantly with influenza vaccine to high-risk elderly individuals. J Infect Dis 2008, 198(9):1317-1326.
160. + T-cell-mediated antiviral protection of the upper respiratory tract in BALB/c mice following parenteral immunization with a recombinant respiratory syncytial virus G protein fragment. J Virol 2000, 74:3455-3463.
161. Plotnicky-Gilquin H., Huss T., Aubrey J-P, et al. Absence of lung immunopathology following respiratory syncytial virus (RSV) challenge in mice immunized with a recombinant RSV G protein fragment. Virology 1999, 258:128-140.
162. Power U.F., Plotnicky-Gilquin H., Huss T., et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 1997, 230:155-166.
163. Power U.F., Nguyen T.N., Rietveld E., et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 2001, 184:1456-1460.
164. Paradiso P.R., Hildreth S.W., Hogerman D.A., et al. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 1994, 13:792-798.
165. Munoz F.M., Piedra P.A., Glezen W.P. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 2003, 21(24):3465-3467.
166. Piedra P.A., Grace S., Jewell A., et al. Sequential annual administration of purified fusion protein vaccine against respiratory syncytial virus in children with cystic fibrosis. Pediatr Infect Dis J 1998, 17:217-224.
167. Calder L.J., González-Reyes L., García-Barreno B., et al. Electron microscopy of the human respiratory syncytial virus fusion protein and complexes that it forms with monoclonal antibodies. Virology 2000, 271:122-131.
168. Swanson K.A., Settembre E.C., Shaw C.A., et al. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 2011, 108:9619-9624.
169. Magro M., Mas V., Chappell K., et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci U S A 2012, 109:3089-3094.
170. Jin H., Zhou H., Cheng X., et al. Recombinant respiratory syncytial viruses with deletions in the NS1, NS2, SH, and M2-2 genes are attenuated in vitro and in vivo. Virology 2000, 273:210-218.
171. Karron R.A., Belshe R.B., Wright P.F., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants. Pediatr Infect Dis J 2003, 22:394-405.
172. McIntosh K., Arbeter A.M., Stahl M.K., et al. Attenuated respiratory syncytial virus vaccines in asthmatic children. Pediatr Res 1974, 8:689-696.
173. Kim H.W., Arrobio J.O., Brandt C.D., et al. Safety and antigenicity of temperature-sensitive (ts) mutant respiratory syncytial virus (RSV) in infants and children. Pediatrics 1973, 52:56-63.
174. Chanock R.M., Murphy B.M. Past efforts to develop safe and effective RSV vaccines. Animal Models of Respiratory Syncytial Virus Infections 1991, 35-42. Mérieux Foundation Publication, Lyon, France. B. Meignier (Ed.).
175. Wright P.F., Shinozaki T., Fleet W., et al. Evaluation of a live, attenuated respiratory syncytial virus vaccine in infants. J Pediatr 1976, 88:931-936.
176. Karron R.A., Wright P.F., Crowe J.E., et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants and children. J Infect Dis 1997, 176:1428-1436.
177. Collins P.L., Hill M.G., Camargo E., et al. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5′ proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci U S A 1995, 92:11563-11567.
178. Collins P.L., Whitehead S.S., Bukreyev A., et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 1999, 54:423-451.
179. Juhasz K., Whitehead S.S., Boulanger C.A., et al. The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations. Vaccine 1999, 17:1416-1424.
180. Whitehead S.S., Firestone C-Y, Collins P.L., et al. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Virology 1998, 247:232-239.
181. Whitehead S.S., Firestone C.Y., Karron R.A., et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 1999, 73:871-877.
182. Bukreyev A., Whitehead S.S., Murphy B.R., et al. Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse. J Virol 1997, 71:8973-8982.
183. Whitehead S.S., Bukreyev A., Teng M.N., et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 1999, 73:3438-3442.
184. Karron R.A., Wright P.F., Belshe R.B., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 2005, 191:1093-1104.
185. Wright P.F., Karron R.A., Madhi S.A., et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 2006, 193:573-581.
186. Spann K.M., Tran K.C., Chi B., et al. Suppression of the induction of alpha, beta and lambda interferons by the NS1 and NS2 proteins of human respiratory syncytial virus in human epithelial cells and macrophages. J Virol 2004, 78:4363-4369.
187. Teng M.N., Whitehead S.S., Bermingham A., et al. Recombinant respiratory syncytial virus that does not express the NS1 or M2-2 protein is highly attenuated and immunogenic in chimpanzees. J Virol 2000, 74:9317-9321.
188. Bernstein D.I., Malkin E., Abughali N., et al. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 2012, 31:109-114.
189. Belshe R.B., Hisson R.K. Cold adaptation of parainfluenza virus type 3: induction of three phenotypic markers. J Med Virol 1982, 10:235-242.
190. Skiadopoulos M.H., Durbin A.P., Tatem J.M., et al. Three amino acid substitutions in the L protein of the human parainfluenza virus type 3 cp45 live attenuated vaccine candidate contribute to its temperature-sensitive and attenuation phenotypes. J Virol 1998, 72:1762-1768.
191. Skiadopoulos M.H., Surman S., Tatem J.M., et al. Identification of mutations contributing to the temperature-sensitive, cold-adapted, and attenuation phenotypes of the live-attenuated cold-passage 45 (cp45) human parainfluenza virus 3 candidate vaccine. J Virol 1999, 73:1374-1381.
192. Coelingh K.L.V., Winter C.C., Murphy B.R. Conserved epitopes of the hemagglutinin-neuraminidase proteins of human and bovine parainfluenza type 3 viruses: nucleotide sequence analysis of variants selected with monoclonal antibodies. J Virol 1986, 60:90-96.
193. Clements M.L., Belshe R.B., King J., et al. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 1991, 29:1175-1182.
194. Karron R.A., Wright P.F., Hall S.L., et al. A live attenuated bovine parainfluenza type 3 virus vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children. J Infect Dis 1995, 171:1107-1114.
195. Karron R.A., Wright P.F., Newman F.K., et al. A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children. J Infect Dis 1995, 172:1445-1450.
196. Belshe R.B., Newman F.K., Tsai T.F., et al. Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old. J Infect Dis 2004, 189:462-470.
197. Schmidt A.C., McAuliffe J.M., Huang A., et al. Bovine parainfluenza virus type 3 (BPIV3) fusion and hemagglutinin-neuraminidase glycoproteins make an important contribution to the restricted replication of BPIV3 in primates. J Virol 2000, 74:8922-8929.
198. Slobod K.S., Shenep J.L., Lujan-Zilbermann J., et al. Safety and immunogenicity of intranasal murine parainfluenza virus type 1 (Sendai virus) in healthy human adults. Vaccine 2004, 22:3182-3186.
199. Skiadopoulos M.H., Surman S.R., Riggs J.M., et al. Sendai virus, a murine parainfluenza virus type 1, replicates to a level similar to human PIV1 in the upper and lower respiratory tract of African green monkeys and chimpanzees. Virology 2002, 297:153-160.
200. Collins P.L., Murphy B.R. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc 2005, 2:166-173.
201. Karron R.A., Collins P.L. Parainfluenza Viruses. Fields Virology 2006, WB Saunders, Philadelphia, vol.1. 5th ed. D.M. Knipe, P.M. Howley (Eds.).